Determination of teicoplanin in human plasma and urine by affinity and reversed-phase high-performance liquid chromatography

Riva, E.; Ferry, N.; Cometti, A.; Cuisinaud, G.; Gallo, Gian Gualberto; Sassard, J

doi:10.1016/0378-4347(87)80383-3

Cited by 33 publications

(11 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The two metabolites were isolated from the smaller band as described above. The HPLC profile of teicoplanin under the conditions generally used (13) gave no indication of the relative amounts of the two metabolites because they coincided (Fig. 3).…”

Section: Methodsmentioning

confidence: 99%

“…Teicoplanin components can be separated by gradient reversed-phase high-pressure liquid chromatography (HPLC) (Fig. 2) (13), by which it has been found that the A3-1 component is more polar than the A2 group components.…”

mentioning

confidence: 99%

“…HPLC assay. Teicoplanin in urine samples and column fractions, as well as the purified metabolites, were analyzed by HPLC by a method based on that of Riva et al (13). Analysis of teicoplanin in urine required preliminary extraction by affinity chromatography.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Teicoplanin metabolism in humans

Bernareggi¹,

Borghi²,

Borgonovi³

et al. 1992

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Teicoplanin, a lipoglycopeptide antibiotic, consists of five major components (A2-1 through A2-5), one hydrolysis component (A3-1), and four minor components (RS-1 through RS-4). All the major components contain an N-acyl-1-D-glucosamine, but they differ in the lengths and branchings of their acyl-aliphatic chains.Previous studies with radiolabeled teicoplanin in rats and humans have shown that the drug is eliminated by the renal route and that metabolic transformation is very minor, about 5%. A possible metabolic transformation of teicoplanin into A3-1 was also suggested. In the present study in humans, two metabolites (metabolites 1 and 2; 2 to 3% of total teicoplanin) were isolated after intravenous administration of radiolabeled teicoplanin. After purification, their structures were determined by fast atom bombardment mass spectroscopy and 'H nuclear magnetic resonance spectroscopy on the basis of the well-known correlations established in this field, and they were found to be new teicoplaninlike molecules, bearing 8-hydroxydecanoic and 9-hydroxydecanoic acyl moieties. This metabolic transformation is likely due to hydroxylation in the Q-2 and Q-1 positions for metabolites 1 and 2, respectively, of the C-10 linear side chain of component A2-3. This might explain the low extent of metabolism of teicoplanin if we consider that only component A2-3 has a linear chain that is susceptible to such oxidation.Teicoplanin (9) is a glycopeptide antibiotic that consists of a mixture of five major components designated A2-1, A2-2, A2-3, A2-4, and A2-5 and one more polar component designated A3-1 (5); minor components are also present (4, 8). All teicoplanin components are glycopeptide analogs with molecular weights that range from 1564.3 to 1907.7. The A3-1 component is the core glycopeptide that is common to all teicoplanin components that have been identified; it has a linear heptapeptide aglycone, an a-D-mannose, and an acetyl-o-D-glucosamine. All the components of the A2 group contain an additional N-acyl-p-D-glucosamine and differ only in the nature of this acyl-aliphatic chain (1, 4, 8) (Fig. 1). Teicoplanin components can be separated by gradient reversed-phase high-pressure liquid chromatography (HPLC) (Fig. 2) (13), by which it has been found that the A3-1 component is more polar than the A2 group components.Recovery studies with radiolabeled teicoplanin in rats (2, 16) and humans (7) following intravenous (i.v.) administration showed that the antibiotic is eliminated mainly by the renal route. In rats, approximately 70% of the administered dose is eliminated in 24 h, and 76% is eliminated in 120 h (2). In humans, elimination is slower; approximately 50% of the administered dose is recovered in the urine collected over 0 to 48 h after drug administration and 80% is recovered by 16 days (7). A study in rats with i.v. administration of teicoplanin showed little metabolic transformation of the antibiotic; in urine collected over 0 to 24 h after drug administration, no more than 3 to 5% of the dose eliminated was fo...

show abstract

Section: Methodsmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Teicoplanin metabolism in humans

Bernareggi¹,

Borghi²,

Borgonovi³

et al. 1992

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…Fluorescence polarization immunoassay, which is a widely used and highly convenient method for determining the plasma concentration of teicoplanin, does not allow separate determinations of individual components of teicoplanin. Some high-performance liquid chromatographic (HPLC) methods for the analysis of teicoplanin components in human plasma have been reported [4][5][6][7][8][9][10]. These HPLC methods are, however, limited by one or more factors, such as detection limitation, potential interference from co-eluting matrix constituents and time-consuming extraction procedures.…”

Section: Introductionmentioning

confidence: 99%

Quantitative determination of individual teicoplanin components in human plasma and cerebrospinal fluid by high-performance liquid chromatography with electrochemical detection

Mochizuki

Ohno

Shimamura

et al. 2007

Journal of Chromatography B

View full text Add to dashboard Cite

“…For affinity chromatography (10,15), each urine sample (1 ml) was adjusted to pH 7.4, and 1 ml of a homogeneous 1:1 (vol/vol) suspension of D-alanyl-D-alanine-e-aminocaproyl-Sepharose resin and 0.05 M phosphate buffer (pH 7.4) containing 0.2 M NaCl (1 ml) was added. After an overnight incubation at 4°C, the suspension was placed on the top of a column containing 6 ml of resin equilibrated with the same buffer.…”

Section: Methodsmentioning

confidence: 99%

Teicoplanin metabolism in rats

Zerilli¹,

Cavenaghi²,

Bernareggi³

et al. 1989

Antimicrob Agents Chemother

View full text Add to dashboard Cite

This study was done to see whether teicoplanin undergoes metabolic transformation in rats. Sprague-Dawley rats were given 7.6 mg of ['4Cjteicoplanin (904 U/mg, 7.6 ,uCi/mg) per kg intravenously; 73.2 ± 4.0% of the administered radioactivity and 59.1 4.8% of the administered microbiological activity were recovered in the 24-h urine samples. The difterence between these two values was due to adsorption of teicoplanin to the urinary sediment, making some of the antibiotic not available for microbiological determination. In fact, after a sample of urine was filtered through an Acrodisc (0.45-,Im pore size), radiochemical and microbiological data for the filtrate were very similar. Possible metabolites were looked for by high-performance liquid chromatographic analysis of the teicoplanin complex composition in the urine samples, with both UV and radioactivity detection.The quantitation, based on the 14C percentage in each peak, showed that no more than 3 to 5% of the [14Cjteicoplanin underwent metabolic and/or chemical transformation.The glycopeptide antibiotic teicoplanin (8, 14) was recently introduced in parenteral treatment of severe infections caused by gram-positive aerobic and anaerobic bacteria (13). Teicoplanin is a complex of six major components which, on the basis of separation by reversed-phase highpressure liquid chromatography (HPLC), are classified into two groups, T-A2 (five compounds) and T-A3 (one compound). T-A3 has been shown to be a hydrolysis product of group T-A2 (i). Minor quantities of related substances are also present (4, 7).The in vitro activity against gram-positive clinical isolates of staphylococci and streptococci, the in vivo activity in mice with septicemic infections (50% effective dose given subeutaneously); and the acute toxicity in mice (50% lethal dose given intraperitoneally) of the individual components of the T-A2 group are similar (5). The T-A3 component shows an in vitro activity comparable to those of the individual components of the T-A2 group against some microorganisms, but it is less active against other bacterial species (11).The disposition of teicoplanin was studied in SpragueDawley rats giveh the 14C-labeled teicoplanin complex intravenodsly (3). The plasma concentration profiles of both total radioactivity and microbiological activity fitted a threeexponential equation, but levels of radioactivity were constantly higher than those determined microbiologically. The mean retoveries of teicoplanin in urine were 76.3% as determihed by radioactivity and 47.1% as determined by microbiology. These data are in keeping with the findings in humans (6,16). In this study we aimed at understanding the reasons for this difference and detecting possible metabolic derivatives of teicoplanin. MATERIALS AND METHODSChemicals.[14C]teicoplanin complex 1 was prepared by mixing the two fractions, T-A2-1/2/3 and T-A2-4/5, of the batch Midland 9/84 API, kindly supplied by C. Snipes (Dow Chemical Co., Midland, Mich.), who obtained it by fermentation with 14C-labeled p-hydroxyphenyl-glyc...

show abstract

Determination of teicoplanin in human plasma and urine by affinity and reversed-phase high-performance liquid chromatography

Cited by 33 publications

References 21 publications

Teicoplanin metabolism in humans

Teicoplanin metabolism in humans

Quantitative determination of individual teicoplanin components in human plasma and cerebrospinal fluid by high-performance liquid chromatography with electrochemical detection

Teicoplanin metabolism in rats

Contact Info

Product

Resources

About